Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo

被引:346
作者
Clayburgh, DR
Barrett, TA
Tang, YM
Meddings, JB
Van Eldik, LJ
Watterson, DM
Clarke, LL
Mrsny, RJ
Turner, JR
机构
[1] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
[2] Northwestern Univ, Div Gastroenterol, Dept Med, Chicago, IL 60611 USA
[3] Univ Alberta, Dept Med, Edmonton, AB, Canada
[4] Northwestern Univ, Ctr Drug Discovery & Chem Biol, Chicago, IL 60611 USA
[5] Univ Missouri, Dept Biomed Sci, Columbia, MO USA
[6] Cardiff Univ, Welsh Sch Pharm, Cardiff, Wales
关键词
D O I
10.1172/JCI24970
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Disruption of the intestinal epithelial barrier occurs in many intestinal diseases, but neither the mechanisms nor the contribution of barrier dysfunction to disease pathogenesis have been defined. We utilized a murine model of T cell-mediated acute diarrhea to investigate the role of the epithelial barrier in diarrheal disease. We show that epithelial barrier dysfunction is required for the development of diarrhea. This diarrhea is characterized by reversal of net water flux, from absorption to secretion; increased leak of serum protein into the intestinal lumen; and altered tight junction structure. Phosphorylation of epithelial myosin II regulatory light chain (MLC), which has been correlated with tight junction regulation in vitro, increased abruptly after T cell activation and coincided with the development of diarrhea. Genetic knockout of long myosin light chain kinase (MLCK) or treatment of wild-type mice with a highly specific peptide MLCK inhibitor prevented epithelial MLC phosphorylation, tight junction disruption, protein leak, and diarrhea following T cell activation. These data show that epithelial MLCK is essential for intestinal barrier dysfunction and that this barrier dysfunction is critical to pathogenesis of diarrheal disease. The data also indicate that inhibition of epithelial MLCK may be an effective non-immunosuppressive therapy for treatment of immune-mediated intestinal disease.
引用
收藏
页码:2702 / 2715
页数:14
相关论文
共 81 条
[1]   Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase) [J].
Amano, M ;
Ito, M ;
Kimura, K ;
Fukata, Y ;
Chihara, K ;
Nakano, T ;
Matsuura, Y ;
Kaibuchi, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (34) :20246-20249
[2]   The specificities of protein kinase inhibitors: an update [J].
Bain, J ;
McLauchlan, H ;
Elliott, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2003, 371 :199-204
[3]  
Berglund JJ, 2001, AM J PHYSIOL-GASTR L, V281, pG1487
[4]   RENAL CLEARANCE OF FERROCYANIDE IN THE DOG [J].
BERLINER, RW ;
KENNEDY, TJ ;
HILTON, JG .
AMERICAN JOURNAL OF PHYSIOLOGY, 1950, 160 (02) :325-329
[5]   Differential regulation of alternatively spliced endothelial cell myosin light chain kinase isoforms by p60Src [J].
Birukov, KG ;
Csortos, C ;
Marzilli, L ;
Dudek, S ;
Ma, SF ;
Bresnick, AR ;
Verin, AD ;
Cotter, RJ ;
Garcia, JGN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (11) :8567-8573
[6]   INTESTINAL PERMEABILITY IN PATIENTS WITH CELIAC-DISEASE AND DERMATITIS-HERPETIFORMIS [J].
BJARNASON, I ;
MARSH, MN ;
PRICE, A ;
LEVI, AJ ;
PETERS, TJ .
GUT, 1985, 26 (11) :1214-1219
[7]   220-and 130-kDa MLCKs have distinct tissue distributions and intracellular localization patterns [J].
Blue, EK ;
Goeckeler, ZM ;
Jin, YJ ;
Hou, L ;
Dixon, SA ;
Herring, BP ;
Wysolmerski, RB ;
Gallagher, PJ .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2002, 282 (03) :C451-C460
[8]   ACTIVATION OF SKELETAL-MUSCLE MYOSIN LIGHT CHAIN KINASE BY CALCIUM(2+) AND CALMODULIN [J].
BLUMENTHAL, DK ;
STULL, JT .
BIOCHEMISTRY, 1980, 19 (24) :5608-5614
[9]  
Breslin NP, 2001, AM J GASTROENTEROL, V96, P2934
[10]   Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease [J].
Brown, GR ;
Lindberg, G ;
Meddings, J ;
Silva, M ;
Beutler, B ;
Thiele, D .
GASTROENTEROLOGY, 1999, 116 (03) :593-601